ERGO (Entia Biosciences) Other Current Liabilities: $0.00 Mil (As of Dec. 2016)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Entia Biosciences Other Current Liabilities?

Entia Biosciences ERGO Other Current Liabilities is $0.00 Mil as of Dec. 2016.

Entia Biosciences's other current liabilities for the quarter that ended in Dec. 2016 was $0.00 Mil.

Entia Biosciences's quarterly other current liabilities declined from Jun. 2016 ($0.00 Mil) to Sep. 2016 ($0.00 Mil) but then from Sep. 2016 ($0.00 Mil) to Dec. 2016 ($0.00 Mil).

Entia Biosciences's annual other current liabilities increased from Dec. 2014 ($-0.00 Mil) to Dec. 2015 ($0.00 Mil) but then stayed the same from Dec. 2015 ($0.00 Mil) to Dec. 2016 ($0.00 Mil).

Entia Biosciences Other Current Liabilities Related Terms

Entia Biosciences Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Entia Biosciences's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Entia Biosciences Other Current Liabilities Chart

Entia Biosciences Annual Data
Trend Jul07 Jul08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.00 0.00 0.00

Entia Biosciences Quarterly Data
Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Entia Biosciences Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $0.00 Mil mean?
Entia Biosciences (ERGO) has a Other Current Liabilities of $0.00 Mil as of Dec. 2016. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Entia Biosciences.
Is Entia Biosciences' Other Current Liabilities too high?
Entia Biosciences' current Other Current Liabilities is $0.00 Mil.
How does Entia Biosciences' Other Current Liabilities compare to OBMP and NSPX?
Entia Biosciences' Other Current Liabilities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Entia Biosciences. Entia Biosciences's current Other Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entia Biosciences stock overvalued right now?
Entia Biosciences (ERGO) has a current Other Current Liabilities of $0.00 Mil. The current Other Current Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Entia Biosciences (ERGO), the current Other Current Liabilities is $0.00 Mil as of Dec. 2016. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Entia Biosciences Business Description

Address 13565 South West Tualatin-Sherwood Road, Suite 800, Sherwood, OR, USA, 97140
Entia Biosciences Inc operates as a biotechnology company, is engaged in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products, principally in the United States of America. It market nutraceutical products under the name GROH and SANO directly to the consumers online. It currently offers natural organic nutraceutical mushroom dietary supplement products, ImmuSANO, GlucoSANO, and GROH, which has been designed to nutritionally support hair follicles and nail beds. It derives its revenue from the sale of its GROH line and mushroom-based nutraceutical dietary supplement products and functional ingredients.